STOCK TITAN

Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Delcath Systems, Inc. to participate in Lytham Partners Fall 2023 Investor Conference
Positive
  • None.
Negative
  • None.

NEW YORK, Oct. 10, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that it will be participating in the Lytham Partners Fall 2023 Investor Conference taking place virtually on Tuesday, October 17, 2023.

Company Webcast

Gerard Michel, CEO, will be participating in a fireside chat. The Company's webcast presentation will be available for viewing at 7:00am ET on Tuesday, October 17, 2023, on the Company's website at https://delcath.com/investors/ or https://wsw.com/webcast/lytham9/dcth/2022008. The webcast will also be archived and available for replay.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register at https://lythampartners.com/fall2023invreg/.  

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (melphalan for Injection/Hepatic Delivery System), approved for use in the United States by FDA, and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), designated under the medical device regulation for use in Europe and the United Kingdom, are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. For more information regarding HEPZATO KIT and its use, including Important Safety Information and Boxed Warning, please visit HEPZATOKIT.com. For more information regarding CHEMOSAT and its use, please visit Chemosat.com.

Contact:
Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/delcath-systems-to-participate-in-the-lytham-partners-fall-2023-investor-conference-301951598.html

SOURCE Delcath Systems, Inc.

FAQ

When is the Lytham Partners Fall 2023 Investor Conference taking place?

The conference is taking place virtually on Tuesday, October 17, 2023.

Who will be participating in a fireside chat at the conference?

Gerard Michel, CEO of Delcath Systems, Inc., will be participating in a fireside chat.

Where can I view the Company's webcast presentation?

The webcast presentation will be available for viewing on the Company's website at https://delcath.com/investors/ or https://wsw.com/webcast/lytham9/dcth/2022008.

Will the webcast be available for replay?

Yes, the webcast will be archived and available for replay.

How can I arrange a one-on-one meeting with management?

To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register at https://lythampartners.com/fall2023invreg/.

Delcath Systems Inc

NASDAQ:DCTH

DCTH Rankings

DCTH Latest News

DCTH Stock Data

138.39M
21.10M
3.21%
27.87%
3.68%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
QUEENSBURY

About DCTH

delcath systems, inc. (nasdaq- dcth) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. our proprietary product---melphalan hydrochloride for injection for use with the delcath hepatic delivery system (melphalan/hds)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. delcath is in late-stage clinical development in the united states with initial commercial activities in europe, where the melphalan/hds is marketed as a ce marked device under the trade name delcath hepatic chemosat® delivery system for melphalan (chemosat). our commercial strategy for chemosat is to steadily grow clinical adoption in major european markets and utilize physician experience to support appeals for reimbursement. since launch over 250 chemosat treatments have been performed at over 20 leading european cancer centers. in 2016, we launched our focus pivotal study in hepatic dominant ocular